Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.

NCT01908621 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: G-CSF (filgrastim)
DRUG: Cytosine arabinoside + G-CSF (filgrastim)

Sponsor

Maria Sklodowska-Curie National Research Institute of Oncology